Search company, investor...

KeyNeurotek Pharmaceuticals

keyneurotek.de

Stage

Series C | Alive

Total Raised

$10.9M

Last Raised

$10.9M | 14 yrs ago

About KeyNeurotek Pharmaceuticals

KeyNeurotek Pharmaceuticals is a clinical stage small molecule company focused on autoimmune and CNS diseases.

Headquarters Location

ZENIT Technology Park Leipziger Str. 44

39120,

Germany

(+490) 391-611-7220

Missing: KeyNeurotek Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: KeyNeurotek Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing KeyNeurotek Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

KeyNeurotek Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

KeyNeurotek Pharmaceuticals Patents

KeyNeurotek Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/15/2004

9/11/2012

Peptidase, Piperazines, Immunology, Piperidines, Carboxamides

Grant

Application Date

10/15/2004

Grant Date

9/11/2012

Title

Related Topics

Peptidase, Piperazines, Immunology, Piperidines, Carboxamides

Status

Grant

Latest KeyNeurotek Pharmaceuticals News

Traumatic Brain Injury Therapeutics Market detailed strategies, Competitive landscaping and recent developments

Aug 4, 2018

HTF MI recently introduced Global Traumatic Brain Injury Therapeutics Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. At present, the market is developing its presence and some of the key players from the complete study are SFC Fluidics LLC, Banayan Biomarkers Inc., BHR Pharma LLC, Cerora Inc., ElMindA Ltd., Grace Laboratories LLC, KeyNeurotek Pharmaceuticals AG, Luoxis Diagnostics, Neuro Assessment Systems, Neurovive Pharmaceuticals AB, Oxygen Biotherapeutics Inc., Phlogistix LLC, Neurohealing Pharmaceuticals, Neuren Pharmaceuticals Ltd., Remedy Pharmaceuticals Inc., Biodirection Inc., Brainscope Company Inc., TEVA Pharmaceutical Industries Ltd. & Vasopharm etc. The market Study is segmented by key regions which is accelerating the marketization. Request Sample of Global Traumatic Brain Injury Therapeutics Market Professional Survey Report 2018 @:  https://www.htfmarketreport.com/sample-report/1151984-global-traumatic-brain-injury-therapeutics-market-3 This report studies the Global Traumatic Brain Injury Therapeutics market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the Global Traumatic Brain Injury Therapeutics market by companies, region, type and end-use industry. Browse 100+ market data Tables and Figures spread through Pages and in-depth TOC on ” Traumatic Brain Injury Therapeutics Market by Type (Acetylcholinesterase Inhibitors, Erythropoietin, Growth Hormone, Stem Cells & Others), by End-Users/Application (Focal TBI, Open TBI, Closed TBI, Diffuse TBI, Primary TBI & Others), Organization Size, Industry, and Region – Forecast to 2023″. Early buyers will receive 10% customization on comprehensive study. In order to get a deeper view of Market Size, competitive landscape is provided i.e. Revenue (Million USD) by Players (2013-2018), Revenue Market Share (%) by Players (2013-2018) and further a qualitative analysis is made towards market concentration rate, product/service differences, new entrants and the technological trends in future. Enquire for customization in Report @  https://www.htfmarketreport.com/enquiry-before-buy/1151984-global-traumatic-brain-injury-therapeutics-market-3 Competitive Analysis: The key players are highly focusing innovation in production technologies to improve efficiency and shelf life. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in the optimal strategies. Company profile section of players such as SFC Fluidics LLC, Banayan Biomarkers Inc., BHR Pharma LLC, Cerora Inc., ElMindA Ltd., Grace Laboratories LLC, KeyNeurotek Pharmaceuticals AG, Luoxis Diagnostics, Neuro Assessment Systems, Neurovive Pharmaceuticals AB, Oxygen Biotherapeutics Inc., Phlogistix LLC, Neurohealing Pharmaceuticals, Neuren Pharmaceuticals Ltd., Remedy Pharmaceuticals Inc., Biodirection Inc., Brainscope Company Inc., TEVA Pharmaceutical Industries Ltd. & Vasopharm includes its basic information like legal name, website, headquarters, its market position, historical background and top 5 closest competitors by Market capitalization / revenue along with contact information. Each player/ manufacturer revenue figures, growth rate and gross profit margin is provided in easy to understand tabular format for past 5 years and a separate section on recent development like mergers, acquisition or any new product/service launch etc. Market Segments: On The Basis Of Type: Acetylcholinesterase Inhibitors, Erythropoietin, Growth Hormone, Stem Cells & Others. On The Basis Of Application: Focal TBI, Open TBI, Closed TBI, Diffuse TBI, Primary TBI & Others On The Basis Of Region, this report is segmented into following key geographies, with production, consumption, revenue (million USD), and market share, growth rate of Traumatic Brain Injury Therapeutics in these regions, from 2013 to 2023 (forecast), covering • North America (U.S. & Canada) {Market Revenue (USD Billion), Growth Analysis (%) and Opportunity Analysis} • Latin America (Brazil, Mexico & Rest of Latin America) {Market Revenue (USD Billion), Growth Share (%) and Opportunity Analysis} • Europe (The U.K., Germany, France, Italy, Spain, Poland, Sweden & RoE) {Market Revenue (USD Billion), Growth Share (%) and Opportunity Analysis} • Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest of Asia) {Market Revenue (USD Billion), Growth Share (%) and Opportunity Analysis} • Middle East & Africa (GCC, South Africa, North Africa, RoMEA) {Market Revenue (USD Billion), Growth Share (%) and Opportunity Analysis} • Rest of World {Market Revenue (USD Billion), Growth Analysis (%) and Opportunity Analysis} Buy Single User License of Global Traumatic Brain Injury Therapeutics Market Professional Survey Report 2018 @  https://www.htfmarketreport.com/buy-now?format=1&report=1151984 Have a look at some extracts from Table of Content Introduction about Global Industrial Pump Rental • Global Traumatic Brain Injury Therapeutics Market Size (Sales) Market Share by Type (Product Category) in 2017 • Traumatic Brain Injury Therapeutics Market by Application/End Users • Global Traumatic Brain Injury Therapeutics Sales (Volume) and Market Share Comparison by Applications • (2013-2023) table defined for each application/end-users like [Focal TBI, Open TBI, Closed TBI, Diffuse TBI, Primary TBI & Others] • Global Traumatic Brain Injury Therapeutics Sales and Growth Rate (2013-2023) • Traumatic Brain Injury Therapeutics Competition by Players/Suppliers, Region, Type and Application • Traumatic Brain Injury Therapeutics (Volume, Value and Sales Price) table defined for each geographic region defined. • Global Traumatic Brain Injury Therapeutics Players/Suppliers Profiles and Sales Data Additionally Company Basic Information, Manufacturing Base and Competitors list is being provided for each listed manufacturers • Market Sales, Revenue, Price and Gross Margin (2013-2018) table for each product type which include Acetylcholinesterase Inhibitors, Erythropoietin, Growth Hormone, Stem Cells & Others • Traumatic Brain Injury Therapeutics Manufacturing Cost Analysis • Traumatic Brain Injury Therapeutics Key Raw Materials Analysis • Traumatic Brain Injury Therapeutics Chain, Sourcing Strategy and Downstream Buyers, Industrial Chain Analysis • Market Forecast (2018-2023) Browse for Full Report at:  https://www.htfmarketreport.com/reports/1151984-global-traumatic-brain-injury-therapeutics-market-3 Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia. About Author: HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”. Contact US : HTF Market Intelligence Consulting Private Limited Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837

KeyNeurotek Pharmaceuticals Frequently Asked Questions (FAQ)

  • What is KeyNeurotek Pharmaceuticals's latest funding round?

    KeyNeurotek Pharmaceuticals's latest funding round is Series C.

  • How much did KeyNeurotek Pharmaceuticals raise?

    KeyNeurotek Pharmaceuticals raised a total of $10.9M.

  • Who are the investors of KeyNeurotek Pharmaceuticals?

    Investors of KeyNeurotek Pharmaceuticals include IBG Beteiligungsgesellschaft, Deutsche Venture Capital and KfW.

  • Who are KeyNeurotek Pharmaceuticals's competitors?

    Competitors of KeyNeurotek Pharmaceuticals include Bellicum Pharmaceuticals, Intercept Pharmaceuticals, Glaukos, Deciphera Pharmaceuticals, PrevaCept Infection Control and 15 more.

Compare KeyNeurotek Pharmaceuticals to Competitors

A
Ausio Pharmaceuticals

Ausio Pharmaceuticals is a company focused on the clinical development of S-Equol for major medical needs.

F
Funxional Therapeutics

Funxional Therapeutics Ltd.'s focus is on broad-spectrum chemokine inhibitors. Its small molecule lead candidate has entered clinical development. The chemokine inhibitors will target a broad range of inflammatory conditions.

A
Aderis Pharmaceuticals

Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.

S
Sequoia Pharmaceuticals

Sequoia Pharmaceuticals, Inc. is engaged in the discovery and development of antiviral therapeutics, with a focus on developing new treatments for drug-resistant infectious diseases such as HIV/AIDS and HCV-induced hepatitis. Sequoia Pharmaceuticals is located in Gaithersburg, Md.

T
Transport Pharmaceuticals

Transport Pharmaceuticals is developing a drug/device platform for the treatment of dermatological diseases

N
NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.